{
    "hands_on_practices": [
        {
            "introduction": "Effective management of an infectious disease outbreak begins with accurate identification of the causative agent. For *Acinetobacter baumannii*, this is challenging due to its close resemblance to other species in the *Acinetobacter calcoaceticus–baumannii* (ACB) complex. This exercise  challenges you to devise a reliable diagnostic workflow, showing how modern clinical labs combine proteomic fingerprinting with species-specific genetic markers to achieve the high degree of certainty needed for patient care and infection control.",
            "id": "4603057",
            "problem": "A clinical laboratory receives a non-fermenting, oxidase-negative Gram-negative coccobacillus recovered from a patient with ventilator-associated pneumonia. The preliminary workup and hospital epidemiology strongly suggest the isolate belongs to the Acinetobacter calcoaceticus–baumannii complex, and the differential of concern is Acinetobacter baumannii, Acinetobacter nosocomialis, or Acinetobacter pittii. The laboratory aims to implement a minimal but reliable workflow consisting of at least one phenotypic test and one genotypic test to distinguish Acinetobacter baumannii from Acinetobacter nosocomialis and Acinetobacter pittii.\n\nUse the following foundational principles to reason toward the optimal choice:\n- Central dogma of molecular biology states that chromosomally encoded species-specific genes are transcribed and translated in a manner that can be detected by molecular assays, and highly conserved, intrinsic chromosomal markers provide stable, species-level signals across isolates.\n- Polymerase Chain Reaction (PCR) amplifies target DNA with high analytical sensitivity and specificity when primers uniquely match species-specific sequences.\n- Protein fingerprinting by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight mass spectrometry (MALDI-TOF MS) compares the measured proteome to a curated database and can distinguish closely related species when the reference library is validated.\n- Phenotypic traits such as growth at elevated temperature (e.g., $44\\,^{\\circ}\\mathrm{C}$) can be stable within a species but may have imperfect sensitivity or specificity across all clinical isolates.\n\nSelect the minimal test set and decision rule that most reliably differentiates Acinetobacter baumannii from Acinetobacter nosocomialis and Acinetobacter pittii in routine clinical practice.\n\nA. Perform a growth test at $44\\,^{\\circ}\\mathrm{C}$ and PCR for chromosomal blaOXA-51-like; classify as Acinetobacter baumannii if either test is positive (logical “OR”), otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n\nB. Perform an oxidase test and sequence the 16S ribosomal RNA gene; classify as Acinetobacter baumannii if the best 16S match is Acinetobacter baumannii in a reference database, otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n\nC. Perform an API $20$NE biochemical panel and PCR for blaOXA-23-like; classify as Acinetobacter baumannii if either test supports Acinetobacter baumannii (logical “OR”), otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n\nD. Identify by MALDI-TOF MS using a validated library and PCR for chromosomal blaOXA-51-like; classify as Acinetobacter baumannii only if both MALDI-TOF MS indicates Acinetobacter baumannii and blaOXA-51-like is detected (logical “AND”), otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n\nE. Sequence a partial fragment of the $rpoB$ gene and classify solely by phylogenetic placement; assign species based on $rpoB$ alone without any phenotypic test.",
            "solution": "The problem statement is evaluated as valid. It presents a scientifically sound and well-posed clinical microbiology scenario. The goal is to devise a minimal, reliable workflow to differentiate *Acinetobacter baumannii* from the closely related species *Acinetobacter nosocomialis* and *Acinetobacter pittii*, using at least one phenotypic and one genotypic test. The foundational principles provided are accurate and relevant. The problem is objective, self-contained, and free of contradictions.\n\nThe core of the problem is to select the combination of tests and the logical rule that provides the highest reliability for identifying *Acinetobacter baumannii*. The species within the *Acinetobacter calcoaceticus–baumannii* (ACB) complex are notoriously difficult to distinguish using traditional biochemical methods due to their high genetic and phenotypic similarity.\n\nA reliable identification strategy must leverage a marker that is both highly sensitive (present in all or nearly all isolates of the target species) and highly specific (absent in other species).\n\n**Derivation of the Optimal Strategy**\n\n1.  **Genotypic Test Evaluation**: According to the provided principle, \"highly conserved, intrinsic chromosomal markers provide stable, species-level signals\". In the context of the ACB complex, the gene *blaOXA-51-like* is a chromosomally encoded, intrinsic carbapenem-hydrolyzing class D $\\beta$-lactamase gene that is naturally present in and exclusive to *A. baumannii*. It is therefore considered the definitive genetic marker for this species. A Polymerase Chain Reaction (PCR) assay for *blaOXA-51-like* is the gold-standard genotypic test to identify *A. baumannii*. Other genetic markers mentioned, such as the 16S rRNA gene, lack the resolution to differentiate these closely related species. The *blaOXA-23-like* gene is typically associated with acquired carbapenem resistance and can be found on mobile genetic elements in various *Acinetobacter* species, making it an unsuitable marker for species identification. Sequencing housekeeping genes like *rpoB* is a powerful method but is a single, purely genotypic approach.\n\n2.  **Phenotypic Test Evaluation**: The problem requires at least one phenotypic test.\n    *   **Growth at $44\\,^{\\circ}\\mathrm{C}$**: This is a classic test. While most *A. baumannii* isolates can grow at this temperature, this trait is not perfectly sensitive (some strains may not grow) nor perfectly specific (some strains of other species, like *A. pittii*, may grow). It is a useful but not definitive characteristic.\n    *   **Commercial biochemical panels (e.g., API $20$NE)**: These are generally unreliable for separating members of the ACB complex due to their overlapping biochemical profiles and intraspecies variability.\n    *   **Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF MS)**: This is a proteomic method that analyzes the protein profile (primarily abundant ribosomal proteins) of an organism. It is fundamentally a measure of a complex phenotype (the expressed proteome). With a robust and validated reference database, MALDI-TOF MS has proven to be a rapid and highly accurate method for differentiating species within the ACB complex. It is considered a state-of-the-art phenotypic identification method in modern clinical microbiology.\n\n3.  **Workflow Synthesis**: The optimal workflow should combine a highly reliable phenotypic/proteomic test with the definitive genotypic test. The combination of MALDI-TOF MS and *blaOXA-51-like* PCR is therefore the most powerful. The logical rule is also critical. An \"AND\" rule (both tests must be positive) provides the highest possible specificity and confidence, ensuring that an isolate is only classified as *A. baumannii* when both the protein fingerprint and the definitive species-specific gene are consistent. This minimizes the risk of false-positive identification, which is crucial for epidemiology and infection control.\n\n**Option-by-Option Analysis**\n\nA. Perform a growth test at $44\\,^{\\circ}\\mathrm{C}$ and PCR for chromosomal blaOXA-51-like; classify as Acinetobacter baumannii if either test is positive (logical “OR”), otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n*   **Analysis**: This workflow combines a moderately reliable phenotypic test with the gold-standard genotypic test. The critical flaw is the logical \"OR\". A non-*baumannii* isolate (e.g., *A. pittii*) that is *blaOXA-51-like* negative but happens to grow at $44\\,^{\\circ}\\mathrm{C}$ would be incorrectly identified as *A. baumannii*. This \"OR\" logic reduces the overall specificity of the workflow to that of its weakest component (the temperature growth test).\n*   **Verdict**: **Incorrect**.\n\nB. Perform an oxidase test and sequence the 16S ribosomal RNA gene; classify as Acinetobacter baumannii if the best 16S match is Acinetobacter baumannii in a reference database, otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n*   **Analysis**: This option is doubly flawed. First, the problem states the isolate is already known to be oxidase-negative, making this test redundant. Second, and more importantly, the 16S rRNA gene does not have sufficient sequence divergence to reliably differentiate between the species of the ACB complex. This method is known to lead to misidentifications.\n*   **Verdict**: **Incorrect**.\n\nC. Perform an API $20$NE biochemical panel and PCR for blaOXA-23-like; classify as Acinetobacter baumannii if either test supports Acinetobacter baumannii (logical “OR”), otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n*   **Analysis**: This workflow relies on two inappropriate methods for species identification. API $20$NE biochemical panels are not reliable for this differentiation. PCR for *blaOXA-23-like* targets an acquired antibiotic resistance gene, not an intrinsic species-defining marker. An isolate can be *A. baumannii* without having *blaOXA-23-like*, and a non-*baumannii* species can acquire it. Using this for speciation is a fundamental error.\n*   **Verdict**: **Incorrect**.\n\nD. Identify by MALDI-TOF MS using a validated library and PCR for chromosomal blaOXA-51-like; classify as Acinetobacter baumannii only if both MALDI-TOF MS indicates Acinetobacter baumannii and blaOXA-51-like is detected (logical “AND”), otherwise classify as Acinetobacter nosocomialis or Acinetobacter pittii.\n*   **Analysis**: This option pairs the most advanced and accurate phenotypic/proteomic method (MALDI-TOF MS) with the definitive species-specific genotypic marker (*blaOXA-51-like*). The logical \"AND\" creates a stringent, confirmatory criterion that maximizes the reliability and specificity of the identification. This represents the current best practice for a dual-method approach to definitively identify *A. baumannii* and separate it from other ACB complex members.\n*   **Verdict**: **Correct**.\n\nE. Sequence a partial fragment of the $rpoB$ gene and classify solely by phylogenetic placement; assign species based on $rpoB$ alone without any phenotypic test.\n*   **Analysis**: While *rpoB* gene sequencing is indeed a highly reliable method for speciation in *Acinetobacter*, this option violates the problem's explicit constraint to \"implement a minimal but reliable workflow consisting of at least one phenotypic test and one genotypic test\". This option proposes only a genotypic test.\n*   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{D}$$"
        },
        {
            "introduction": "Once *A. baumannii* is identified, understanding its resistance mechanisms is paramount. This practice  takes you to the molecular level, focusing on the enzymatic activity of the OXA-23 beta-lactamase, a key driver of carbapenem resistance. By applying Michaelis-Menten kinetics to calculate and compare the enzyme's hydrolytic efficiency ($k_{\\text{cat}}/K_M$) against different antibiotics, you will gain a quantitative understanding of how resistance works at a biochemical level.",
            "id": "4603071",
            "problem": "Acinetobacter baumannii produces the class D beta-lactamase Oxacillinase-23 (OXA-23), which hydrolyzes carbapenems during infection. Consider the minimal enzyme mechanism for a single-substrate reaction, $E + S \\rightleftharpoons ES \\rightarrow E + P$, under initial rate conditions where product formation does not significantly change the substrate concentration. Using the Michaelis–Menten formalism for this mechanism, and starting from the definitions of the catalytic rate constant $k_{\\text{cat}}$ and the Michaelis constant $K_M$ as parameters that characterize the turnover of the enzyme–substrate complex and the effective affinity of the enzyme for the substrate, respectively, derive the expression that relates the initial velocity $v_0$ to the substrate concentration $[S]$ when $[S] \\ll K_M$. From that relationship, identify the per-enzyme proportionality constant linking $v_0$ to $[S]$ and explain its interpretation as a measure of hydrolytic efficiency.\n\nTwo carbapenems are assessed as substrates of OXA-23: meropenem and imipenem. Experimentally determined parameters for OXA-23 are provided as follows: for meropenem, $k_{\\text{cat}}=50\\,\\text{s}^{-1}$ and $K_M=100\\,\\mu\\text{M}$; for imipenem, $k_{\\text{cat}}=25\\,\\text{s}^{-1}$ and $K_M=50\\,\\mu\\text{M}$. Compute the hydrolytic efficiencies for these substrates, defined by the per-enzyme constant you derived, for each substrate, and then compute the ratio of meropenem efficiency to imipenem efficiency. Express efficiencies in $\\text{M}^{-1}\\,\\text{s}^{-1}$ and the ratio as a dimensionless number. Round all reported quantities to $3$ significant figures.",
            "solution": "The problem is validated as scientifically grounded, well-posed, and objective. It describes a standard problem in enzyme kinetics based on established principles and provides all necessary information for a unique solution.\n\nThe initial velocity, $v_0$, of an enzyme-catalyzed reaction following the mechanism $E + S \\rightleftharpoons ES \\rightarrow E + P$ is described by the Michaelis–Menten equation:\n$$v_0 = \\frac{V_{\\text{max}} [S]}{K_M + [S]}$$\nwhere $[S]$ is the substrate concentration, $K_M$ is the Michaelis constant, and $V_{\\text{max}}$ is the maximum possible reaction velocity. The maximum velocity is related to the total enzyme concentration, $[E]_T$, and the catalytic rate constant, $k_{\\text{cat}}$, by the expression:\n$$V_{\\text{max}} = k_{\\text{cat}} [E]_T$$\nSubstituting this definition into the Michaelis–Menten equation yields:\n$$v_0 = \\frac{k_{\\text{cat}} [E]_T [S]}{K_M + [S]}$$\nThe problem requires us to consider the specific case where the substrate concentration is much less than the Michaelis constant, i.e., $[S] \\ll K_M$. Under this condition, the sum in the denominator can be approximated as:\n$$K_M + [S] \\approx K_M$$\nSubstituting this approximation into the equation for $v_0$ gives the relationship for the initial velocity at low substrate concentrations:\n$$v_0 \\approx \\frac{k_{\\text{cat}} [E]_T [S]}{K_M}$$\nThis equation can be rearranged to highlight the proportionality between $v_0$ and $[S]$:\n$$v_0 \\approx \\left(\\frac{k_{\\text{cat}}}{K_M}\\right) [E]_T [S]$$\nThe problem asks for the *per-enzyme* proportionality constant. This refers to the intrinsic property of the enzyme that does not depend on the total enzyme concentration $[E]_T$. We can find this by considering the reaction velocity per unit of enzyme concentration, $\\frac{v_0}{[E]_T}$:\n$$\\frac{v_0}{[E]_T} \\approx \\left(\\frac{k_{\\text{cat}}}{K_M}\\right) [S]$$\nFrom this expression, the proportionality constant linking the specific activity of the enzyme, $\\frac{v_0}{[E]_T}$, to the substrate concentration, $[S]$, is the term $\\frac{k_{\\text{cat}}}{K_M}$. This parameter is known as the specificity constant or catalytic efficiency.\n\nThe interpretation of $\\frac{k_{\\text{cat}}}{K_M}$ as a measure of hydrolytic efficiency stems from its physical meaning. When $[S] \\ll K_M$, the vast majority of enzyme molecules are free ($[E]_{\\text{free}} \\approx [E]_T$) and not bound to substrate. The overall rate of the reaction is therefore limited by the frequency of encounters between enzyme and substrate that lead to product formation. The term $\\frac{k_{\\text{cat}}}{K_M}$ functions as an apparent second-order rate constant for the reaction between the enzyme and the substrate ($E + S \\rightarrow E + P$). A high value for this constant indicates high efficiency. This can be achieved by a high $k_{\\text{cat}}$ (rapid turnover of the substrate once the enzyme-substrate complex is formed) and/or a low $K_M$ (high effective affinity of the enzyme for the substrate, meaning the enzyme can function efficiently even at low substrate concentrations). Thus, $\\frac{k_{\\text{cat}}}{K_M}$ provides a comprehensive measure of an enzyme's ability to process a given substrate.\n\nWe are asked to compute this hydrolytic efficiency, $\\frac{k_{\\text{cat}}}{K_M}$, for two substrates of OXA-23: meropenem and imipenem. The units must be $\\text{M}^{-1}\\,\\text{s}^{-1}$, so the given $K_M$ values in $\\mu\\text{M}$ must be converted to $\\text{M}$ using the conversion $1\\,\\mu\\text{M} = 10^{-6}\\,\\text{M}$.\n\nFor meropenem:\n$k_{\\text{cat, mer}} = 50\\,\\text{s}^{-1}$\n$K_{M, \\text{mer}} = 100\\,\\mu\\text{M} = 100 \\times 10^{-6}\\,\\text{M} = 1.00 \\times 10^{-4}\\,\\text{M}$\nThe hydrolytic efficiency for meropenem is:\n$$\\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_{\\text{mer}} = \\frac{50\\,\\text{s}^{-1}}{1.00 \\times 10^{-4}\\,\\text{M}} = 50 \\times 10^{4}\\,\\text{M}^{-1}\\,\\text{s}^{-1} = 5.00 \\times 10^{5}\\,\\text{M}^{-1}\\,\\text{s}^{-1}$$\n\nFor imipenem:\n$k_{\\text{cat, imi}} = 25\\,\\text{s}^{-1}$\n$K_{M, \\text{imi}} = 50\\,\\mu\\text{M} = 50 \\times 10^{-6}\\,\\text{M} = 5.00 \\times 10^{-5}\\,\\text{M}$\nThe hydrolytic efficiency for imipenem is:\n$$\\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_{\\text{imi}} = \\frac{25\\,\\text{s}^{-1}}{5.00 \\times 10^{-5}\\,\\text{M}} = 5.00 \\times 10^{5}\\,\\text{M}^{-1}\\,\\text{s}^{-1}$$\n\nFinally, we compute the ratio of the efficiency for meropenem to that for imipenem:\n$$\\text{Ratio} = \\frac{\\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_{\\text{mer}}}{\\left(\\frac{k_{\\text{cat}}}{K_M}\\right)_{\\text{imi}}} = \\frac{5.00 \\times 10^{5}\\,\\text{M}^{-1}\\,\\text{s}^{-1}}{5.00 \\times 10^{5}\\,\\text{M}^{-1}\\,\\text{s}^{-1}} = 1.00$$\nThe ratio is a dimensionless number. The results, rounded to $3$ significant figures, indicate that OXA-23 hydrolyzes both carbapenems with equal efficiency under conditions of low substrate concentration.",
            "answer": "$$\\boxed{\\begin{pmatrix} 5.00 \\times 10^{5} & 5.00 \\times 10^{5} & 1.00 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Faced with a carbapenem-resistant *A. baumannii* infection, clinicians must often rely on last-resort antibiotics like colistin, which have a narrow therapeutic window. This final practice  bridges the gap between microbiology and clinical pharmacology, guiding you through the essential calculation of a drug dosage. By using fundamental pharmacokinetic principles, you will determine the maintenance dose required to achieve a therapeutic concentration, a critical skill for ensuring treatment efficacy while minimizing potential toxicity.",
            "id": "4603045",
            "problem": "A critically ill patient in the intensive care unit has a bloodstream infection caused by carbapenem-resistant Acinetobacter baumannii. As part of combination therapy, the patient will receive colistin methanesulfonate (CMS), the inactive prodrug that is systemically converted to colistin (also called polymyxin E). For concentration-dependent killing against Acinetobacter baumannii, a clinically chosen target average steady-state plasma concentration of colistin is $C_{\\text{ss,avg}} = 2\\,\\text{mg/L}$. Assume linear pharmacokinetics with time-invariant clearance and that the systemic clearance of colistin for this patient is $CL = 3\\,\\text{L/h}$. The dosing interval for CMS is set to $\\tau = 12\\,\\text{h}$. Ignore loading doses and assume complete conversion of CMS to colistin such that dosing can be expressed as milligrams of colistin base activity (CBA).\n\nStarting from fundamental pharmacokinetic definitions, including that clearance for a drug with linear disposition is defined by $CL = \\frac{R_{\\text{elim}}}{C}$, where $R_{\\text{elim}}$ is the rate of elimination and $C$ is concentration, and that at steady state the average input rate equals the average elimination rate, derive the maintenance dose per dosing interval required to achieve the target $C_{\\text{ss,avg}}$. Express the final dose in milligrams of colistin base activity (mg CBA), and round your answer to three significant figures.",
            "solution": "The problem as stated is scientifically grounded, self-contained, and well-posed. All provided data and conditions are consistent with established principles of pharmacokinetics and clinical reality. Therefore, a solution can be derived.\n\nThe objective is to determine the maintenance dose, denoted by $D_m$, required to achieve a target average steady-state plasma concentration, $C_{\\text{ss,avg}}$. The analysis begins from the fundamental principle of pharmacokinetics at steady state: the average rate of drug administration must equal the average rate of drug elimination. This can be expressed as:\n$$ \\bar{R}_{\\text{in}} = \\bar{R}_{\\text{elim}} $$\nwhere $\\bar{R}_{\\text{in}}$ is the average rate of drug input and $\\bar{R}_{\\text{elim}}$ is the average rate of drug elimination.\n\nFirst, we formalize the average rate of input, $\\bar{R}_{\\text{in}}$. A maintenance dose $D_m$ is administered at a constant dosing interval $\\tau$. The problem specifies to assume complete conversion of the prodrug colistin methanesulfonate (CMS) to its active form, colistin. This is equivalent to assuming a bioavailability factor, $F$, of $1$. The dose is given in units of colistin base activity (CBA), which represents the mass of active colistin. The average rate of drug input into the systemic circulation is thus the total amount of active drug entering the system per dosing interval, divided by the length of that interval:\n$$ \\bar{R}_{\\text{in}} = \\frac{F \\cdot D_m}{\\tau} $$\nGiven $F=1$, this simplifies to:\n$$ \\bar{R}_{\\text{in}} = \\frac{D_m}{\\tau} $$\n\nNext, we formalize the average rate of elimination, $\\bar{R}_{\\text{elim}}$. The problem provides the definition of clearance, $CL$, for a drug with linear disposition:\n$$ CL = \\frac{R_{\\text{elim}}}{C} $$\nwhere $R_{\\text{elim}}$ is the instantaneous rate of elimination and $C$ is the corresponding plasma concentration. This relationship can be rearranged to express the instantaneous elimination rate as a function of concentration:\n$$ R_{\\text{elim}}(t) = CL \\cdot C(t) $$\nwhere $C(t)$ is the plasma concentration at time $t$. Since clearance, $CL$, is assumed to be time-invariant, it is a constant.\n\nThe average rate of elimination over one dosing interval at steady state is the integral of the instantaneous elimination rate over the interval $\\tau$, divided by the length of the interval:\n$$ \\bar{R}_{\\text{elim}} = \\frac{1}{\\tau} \\int_{t_{\\text{ss}}}^{t_{\\text{ss}}+\\tau} R_{\\text{elim}}(t) \\,dt $$\nwhere the integral is taken over any single dosing interval once steady state has been reached. Substituting the expression for $R_{\\text{elim}}(t)$:\n$$ \\bar{R}_{\\text{elim}} = \\frac{1}{\\tau} \\int_{t_{\\text{ss}}}^{t_{\\text{ss}}+\\tau} CL \\cdot C(t) \\,dt $$\nAs $CL$ is constant, it can be moved outside the integral:\n$$ \\bar{R}_{\\text{elim}} = CL \\cdot \\left( \\frac{1}{\\tau} \\int_{t_{\\text{ss}}}^{t_{\\text{ss}}+\\tau} C(t) \\,dt \\right) $$\nThe term in the parentheses is, by definition, the average plasma concentration at steady state, $C_{\\text{ss,avg}}$:\n$$ C_{\\text{ss,avg}} = \\frac{1}{\\tau} \\int_{t_{\\text{ss}}}^{t_{\\text{ss}}+\\tau} C(t) \\,dt $$\nTherefore, the average rate of elimination can be expressed simply as:\n$$ \\bar{R}_{\\text{elim}} = CL \\cdot C_{\\text{ss,avg}} $$\n\nNow, equating the average rate of input and the average rate of elimination at steady state:\n$$ \\frac{D_m}{\\tau} = CL \\cdot C_{\\text{ss,avg}} $$\nWe can now solve for the maintenance dose, $D_m$, by multiplying both sides by the dosing interval $\\tau$:\n$$ D_m = CL \\cdot C_{\\text{ss,avg}} \\cdot \\tau $$\n\nThe problem provides the following values:\nTarget average steady-state concentration: $C_{\\text{ss,avg}} = 2\\,\\text{mg/L}$\nSystemic clearance: $CL = 3\\,\\text{L/h}$\nDosing interval: $\\tau = 12\\,\\text{h}$\n\nSubstituting these values into the derived equation for $D_m$:\n$$ D_m = (3\\,\\text{L/h}) \\cdot (2\\,\\text{mg/L}) \\cdot (12\\,\\text{h}) $$\nThe units are dimensionally consistent: $\\frac{\\text{L}}{\\text{h}} \\times \\frac{\\text{mg}}{\\text{L}} \\times \\text{h} = \\text{mg}$.\n\nPerforming the calculation:\n$$ D_m = 3 \\cdot 2 \\cdot 12\\,\\text{mg} $$\n$$ D_m = 6 \\cdot 12\\,\\text{mg} $$\n$$ D_m = 72\\,\\text{mg} $$\nThe problem asks for the answer to be rounded to three significant figures. The calculated value of $72\\,\\text{mg}$ can be expressed as $72.0\\,\\text{mg}$ to meet this requirement. The dose is in units of milligrams of colistin base activity (mg CBA).",
            "answer": "$$\\boxed{72.0}$$"
        }
    ]
}